Intellia Therapeutics
About Intellia Therapeutics
Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
- Founded
- 2014
- CEO
- Dr. John M. Leonard, M.D.
- Employees
- 377
- Headquarters
- Cambridge, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- intelliatx.com
Company profile
- Exchange
- US
- Symbol
- NTLA
- Market-cap rank
- #2899
- Listing date
- 2016-05-06
- Market cap
- 1.40B
- Float cap
- 1.34B
- Shares out
- 140.36M
- Float shares
- 134.45M
Sectors & themes
Quote time 2026-11-20 20:01:29 · For reference only, not investment advice and not tailored to your situation.
Intellia Therapeutics discussion 0 comments